Abbott Labs, $1.6 billion

U.S. ex rel. McCoyd v. Abbott Laboratories,
Western District of Virginia.

The firm’s attorneys, in conjunction with state and federal governments, pursued claims against Abbot Laboratories, alleging that Abbot unlawfully marketed its anti-epileptic drug, Depakote, to children and nursing home patients.  Their efforts on behalf of the lead whistleblower lead to a $1.6 billion recovery for federal and state governments, one of the largest recoveries under the False Claims Act in a pharmaceutical case involving a single drug, as well as the institution of a  corporate integrity agreement that places compliance burdens on Abbott’s corporate management.